文献类型：期刊文献

英文题名：A pooled analysis of the incidence and mortality risk of atrial fibrillation in patients with COVID-19

作者：Shen, Nan-Nan[1];Wang, Jia-Liang[1];Liu, Xin-Wen[1];Fu, Yong-Ping[2];Chen, Xue-Fang[3]

机构：[1]Shaoxing Univ, Dept Pharm, Affiliated Hosp, Shaoxing, Zhejiang, Peoples R China;[2]Shaoxing Univ, Affiliated Hosp, Dept Cardiol, Shaoxing, Zhejiang, Peoples R China;[3]Shaoxing Univ, Dept Med Lab Sci, Affiliated Hosp, Shaoxing, Zhejiang, Peoples R China

年份：2024

卷号：12

期号：10

外文期刊名：PEERJ

收录：SCI-EXPANDED(收录号：WOS:001338178400001)、、Scopus(收录号：2-s2.0-85206847906)、WOS

基金：This study was supported by the Health Science and Technology Project of Shaoxing (2023SKY079) , the Clinical Medical Research Special Fund Project of Zhejiang Medical Association (2023ZYC-A55) , the Clinical Medical Research Special Fund Project of Zhejiang Medical Association (2022ZYC-Z37) , the Program of General Scientific Project of Zhejiang Education Department (Y202249053) , the Research Project of Grassrootshealth science of Zhejiang Province (2022ZD09) , and the Zhejiang Pharmaceutical Society Hospital pharmacy special research project (2016ZYY29) . The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

语种：英文

外文关键词：Atrial fi brillation; COVID-19; Prevalence; Mortality

外文摘要：Background: There exist serious cardiovascular complications subsequent to SARSCov2 infection (COVID-19); however, the association between COVID-19 and atrial fi brillation (AF) remains to be elucidated. We aimed to assess the prevalence of AF among COVID-19 patients and its associated risk of death. Methods: The present systematic review was performed in accordance with the PRISMA guidelines. The protocol was registered with CRD42022306523. A comprehensive literature search was performed across PubMed, Embase, and Cochrane databases to identify studies reporting on the prevalence of pre-existing or new-onset fi brillation (AF), and/or the associated clinical outcomes in patients with COVID-19 from January 2020 to December 2023. The random-effect model was used to estimate the prevalence of AF and its related mortality. Results: A total of 80 studies, including 39,062,868 COVID-19 patients, were identified fi ed in the present investigation. The prevalence rates of pre-existing AF or new-onset AF were 10.5% (95% CI [9.3-11.7%]) - 11.7%]) or 10.3% (95% CI [6.2-14.5%]), - 14.5%]), respectively. Subgroup analysis revealed a two fold higher incidence of AF in older patients (>= 65 >= 65 years) compared to younger patients (<65 years) (14.4% vs. 6.4%). The highest rate of AF was observed in Europeans (10.7%, 95% CI [10.2-11.2%]), - 11.2%]), followed by Northern Americans (10.0%, 95% CI [8.2-11.7%]), - 11.7%]), while Asians demonstrated a lower prevalence (2.7%, 95% CI [2.2-3.3%]). - 3.3%]). Notably, severe COVID-19 patients displayed a significantly fi cantly elevated prevalence of AF at 14.l% (95% CI [13.3-14.9%]), - 14.9%]), which was approximately 2.5-fold higher than that in non-severe patients (5.2%, 95% CI [4.8-5.5%]). - 5.5%]). Both pre-existing (HR: 1.83, 95% CI [1.49-2.17]) - 2.17]) and new-onset AF (HR: 3.47, 95% CI [2.26-5.33]) - 5.33]) were associated with an increased mortality risk among COVID-19 patients. Furthermore, the effect on mortality risk was more significant fi cant in Asians (HR: 5.33, 95% CI [1.62-9.04]), - 9.04]), compared to Europeans (HR: 1.68, 95% CI [1.24-2.13]) - 2.13]) and North Americans (HR: 2.01, 95% CI [1.18-2.83]). - 2.83]). Conclusion: This study comprehensively investigated the association between AF and COVID-19 in a real-world setting. Notably, a high prevalence of AF was observed among older individuals, severe COVID-19 patients, and in Europe and Northern America. Moreover, co-existing AF was found to be associated with an increased risk for mortality. Further investigations are warranted to improve the management and outcomes of COVID-19 patients with AF.